Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Suxamethonium dosage in electroconvulsive therapy.

W H Konarzewski1, D Milosavljevic, M Robinson

  • 1Colchester General Hospital, Essex.

Anaesthesia
|June 1, 1988
PubMed
Summary

Electroconvulsive therapy (ECT) requires muscle relaxants like suxamethonium. A study found 25 mg of suxamethonium offered practical advantages in ECT, balancing recovery time and seizure modification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Leukemia·2012
Same author

Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages.

FEBS letters·2002
Same author

Conscious sedation with midazolam or propofol does not alter left ventricular diastolic performance in patients with preexisting diastolic dysfunction: a transmitral and tissue Doppler transthoracic echocardiography study.

Anesthesia and analgesia·2001
Same author

Imaging of small-scale features on 433 Eros from NEAR: evidence for a complex regolith.

Science (New York, N.Y.)·2001
Same author

Laser altimetry of small-scale features on 433 Eros from NEAR-Shoemaker.

Science (New York, N.Y.)·2001
Same author

Comparison of glycocalicin, thrombopoietin and reticulated platelet measurement as markers of platelet turnover in HIV+ samples.

Platelets·2001

Area of Science:

  • Anesthesiology
  • Neurology
  • Pharmacology

Background:

  • Electroconvulsive therapy (ECT) is a medical treatment for severe mental health conditions.
  • Neuromuscular blocking agents are used during ECT to prevent injury.
  • Suxamethonium is a common neuromuscular blocking agent, but optimal dosing for ECT requires investigation.

Purpose of the Study:

  • To compare the effects of different suxamethonium doses (15 mg, 25 mg, 50 mg) during electroconvulsive therapy (ECT).
  • To evaluate the impact of suxamethonium dosage on respiratory recovery and seizure modification.
  • To determine the optimal suxamethonium dose for ECT procedures.

Main Methods:

  • A double-blind, randomized study involving 52 patients undergoing 180 ECT treatments.

Related Experiment Videos

  • Patients received suxamethonium at doses of 15 mg, 25 mg, or 50 mg.
  • Outcomes measured included time to spontaneous respiration and quality of seizure modification.

    • Main Results:

    • The 50 mg suxamethonium group had significantly longer recovery times compared to lower doses.
    • Higher suxamethonium doses (50 mg) were associated with better seizure modification than the 15 mg dose.
    • No significant differences in post-treatment muscle pain were observed across dose groups.

    Conclusions:

    • All tested suxamethonium doses (15 mg, 25 mg, 50 mg) were deemed acceptable for ECT.
    • A 25 mg dose of suxamethonium presents practical advantages over 50 mg and theoretical benefits over 15 mg.
    • The 25 mg dose offers a favorable balance between respiratory recovery and seizure modification in ECT.